AzTrials
AzTrials

WoundsNCT01378728

Clinical Validation of a 'Hand-held' Fluorescence Digital Imaging Device for Wound Care Applications

An observational study of Wounds, run by University Health Network, Toronto at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary objective of this clinical study is to evaluate the use and effectiveness of our 'handheld' fluorescence digital imaging device platform for real-time non-invasive clinical monitoring of chronic wounds for healing and bacterial contamination/infectious status over time. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Wounds
How many people
75 participants
Where
1 siteCanada
Study dates
Feb 2009to Apr 2017
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: All patients previously diagnosed with chronic and/or acute wounds will be considered for eligibility into this study.

Who may be able to join

  • Patients will be included in the study according to the following criteria:
  • > 18 years of age
  • males and females
  • presenting with chronic wounds (i.e., diabetic ulcers, etc.), with known or unknown infection status.

Who cannot join

  • Patients will be excluded in the study according to the following criteria:
  • treatment with an investigational drug within 1 month before study enrolment
  • any contra-indication to routine wound care and/or monitoring
  • patients with pre-existing skin issues (e.g. melanomas, psoriasis) in areas close to wound(s) that will be studied
  • inability to consent

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • University Health Network

    Toronto, Ontario, M5G 2M9

Other trials in Canada

About this study

Official title: Clinical Validation Study of a 'Hand-held' Point-of-Care Fluorescence Digital Imaging Device for Real-time Detection and Diagnosis of Wound Infections and Longitudinal Monitoring of Wound Healing Status

The primary objective of this clinical study is to evaluate the use and effectiveness of our 'handheld' fluorescence digital imaging device platform for real-time non-invasive clinical monitoring of chronic wounds for healing and bacterial contamination/infectious status over time. This will enable us to determine if the device can detect and longitudinally track intrinsic changes that may occur during the wound healing process including, but not limited to, collagen re-modeling and bacterial infection of the wound site.

Read the detailed description

Introduction and Rationale:

Wound care is a major clinical challenge and presents an enormous burden to health care worldwide. As wounds (chronic and acute) heal, a number of key biological changes occur at the wound site at the tissue and cellular level. Among these are inflammation, reformation of the epidermal barrier, and remodeling of the connective tissue in the dermis. However, a common major complication arising during the wound healing process, which can range from days to months, is bacterial infection. This can result in a serious impediment to the healing process and lead to significant complications, especially in chronic non-healing wounds. Currently, the standard wound care includes monitoring for possible infection by direct visual inspection under white light and by taking samples for analysis in the laboratory which takes approximately two days to provide a result. However, qualitative visual assessment only provides a gross view of the wound site (i.e., presence of purulent material and crusting) but does not provide the critically important information about underlying changes that are occurring at the tissue and cellular level (i.e., infection, matrix remodeling, inflammation, and necrosis).

All chronic wounds contain bacteria. But whether the wound is in bacterial balance (contamination with organisms on the surface or colonization with organisms in the tissue arranged in micro colonies without causing damage) or bacterial imbalance (critical colonization and infection) is of primary importance to healing. It is important to note that there is a continuum of bacterial presence pro¬gressing from bacterial balance to bacterial damage in a chronic wound. The diagnosis of infection is typically made clinically based on signs and symptoms in and around the local wound bed, the deeper structures, and the surrounding skin. The presence and severity of bacterial infection is typically diagnosed based on the clinical appearance of the wound under white light (i.e., pain, purulent exudate, crusting, swelling, erythema, heat). A major problem is that bacterial contamination within and around a wound cannot be determined directly by visualization of the bacteria themselves under white light, but is based on clinical signs and symptoms caused by bacterial contamination and/or infection within the wound (i.e., pain, purulent exudate, crusting, swelling, erythema, heat).

The remodeling and healing of connective tissues in wounds involves simultaneous synthesis and degradation of collagen fibrils. These bacteria include common species typically found at wound sites (i.e., Staphylococcus and Pseudomonas species). Bacterial swabs are collected at the time of wound examination and have the advantage of providing identification of specific bacterial/microbial species and quantification of bacterial burden. However, often, multiple swabs are collected randomly from the wound site and these are not targeted, and some swabbing techniques may spread the microorganisms around with the wound during the collection process, thus affecting patient healing time and morbidity. This may be a problem especially with large chronic (non-healing) wounds where the detection yield for bacterial presence is suboptimal, despite the collection of multiple swabs. Furthermore, bacteriological culture results often take about 2-4 days to come back from the laboratory, thus significantly delaying diagnosis and treatment. Thus, bacterial swabs do not provide real-time detection of infectious status of wounds. In addition, although wound swabbing appears to be straightforward, it can lead to inappropriate treatment, patient morbidity and increased hospital stays if not performed correctly. An image-based method that allows real-time monitoring of wound healing, particularly early dermal connective tissue remodeling, and the presence of bacterial contamination and/or infection over time could have a significant clinical impact.

Autofluorescence imaging has been used in gastroenterology to image both collagen and bacterial fluorescence in clinical studies. We wish to expand the use of tissue autofluorescence imaging technology to wound care and management in order to provide obtain biologically relevant information of the wound site at the tissue and biomolecular levels in real-time during the healing process. When used to assess wounds, tissue autofluorescence may aid in determining the degree of wound healing and the presence of bacterial infection. In preliminary preclinical testing, we have discovered that when wounds are illuminated a specific wavelength combination of excitation light, endogenous tissue components emit a characteristic fluorescent signal, while bacteria emit a unique fluorescence signal.

We have recently developed an innovative optical molecular imaging platform based on high-resolution fluorescence and white-light technologies in a hand-held, real-time, high-resolution, non-invasive (e.g. non-contact) format. This invention offers real-time detection of important biological and molecular information of a wound for the first time, and could have significant impact on improving conventional wound care and management. Based on extensive preclinical testing, the proposed technology has the capability of collecting autofluorescence images of wounds and detecting the presence and relative changes in connective tissue content and biodistribution involved in wound healing. It can also detect the earliest indication of bacterial/microorganism contamination within the wound (that are occult to standard white light visually-based assessment), thus providing a measure of infection status. This could significantly impact clinical wound care and management by i) reducing the complications associated with missed detection of bacteria infection, ii) facilitating image-guided swabbing/biopsy and iii) monitor wound healing over time. Furthermore, the compact and portable design of the imaging device platform makes it ideal for the clinical wound care environment as well as for point-of-care use for home-health care visits.

Study Objectives and Specific Aims

The primary objective of this clinical study is to evaluate the use and effectiveness of our 'handheld' fluorescence digital imaging device platform for real-time non-invasive clinical monitoring of chronic wounds for healing and bacterial contamination/infectious status over time. This will enable us to determine if the device can detect and longitudinally track intrinsic changes that may occur during the wound healing process including, but not limited to, collagen re-modeling and bacterial infection of the wound site.

As a secondary objective, we wish to obtain valuable end-user data on the clinical utility of the device within the wound clinic environment. This information will be used to optimize subsequent versions of the device during product development.

Most importantly, we hope to conclusively verify the added value that this imaging device brings to traditional wound care practice, and to what extent it will change the gold standard.

Specific Aims:

  1. To determine if the fluorescence imaging device can detect changes in connective tissue over time that can be correlated with wound healing or re-modeling, compared with changes in wound size over time.
  2. To determine the effectiveness of the fluorescence imaging device in detecting the presence (or contamination) of bacteria in and around a wound (including infection), compared with standard best practice methods (e.g. white light visualization and clinical signs and symptoms, with swabbing and bacteriology as the 'gold standard').
  3. To identify the relationships between autofluorescence imaging of tissues and bacteria in wounds (including the wound margin) and the following: i) clinical signs of infection, ii) microbial load (i.e., number of organisms per gram of wound tissue), and iii) diversity of microbial species in the wound (i.e., number of different species isolated per wound), and Gram signing.
Conditions
Wounds
Keywords
Optical imaging, Fluorescence imaging, Chronic and acute wounds, Wound bacteria, Bacterial biofilms, Pathogenic bacteria, Microorganisms, Wound infection, Wound healing, Treatment response assessment
Medical subject headings
Wounds and Injuries, Bronchiolitis Obliterans Syndrome, Wound Infection

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01378728
Study groupRoleWhat they receive
Patients with chronic or acute wounds.Patients with chronic or acute wounds.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. wound size, bacterial load

    Measured: 3 weeks after imaging with device

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Jun 2011 (estimated)
  2. Study startFeb 2009
  3. Primary completionApr 2017
  4. Study completionApr 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
75 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01378728
Sponsor's protocol ID
PRODIGI Wound Imaging Trial
Status last verified
May 2017
First submitted
20 Jun 2011
Last updated
19 May 2017
Results posted
No
Data monitoring committee
Yes

Publications

  • DaCosta RS, Kulbatski I, Lindvere-Teene L, Starr D, Blackmore K, Silver JI, Opoku J, Wu YC, Medeiros PJ, Xu W, Xu L, Wilson BC, Rosen C, Linden R. Point-of-care autofluorescence imaging for real-time sampling and treatment guidance of bioburden in chronic wounds: first-in-human results. PLoS One. 2015 Mar 19;10(3):e0116623. doi: 10.1371/journal.pone.0116623. eCollection 2015.

    PubMed 25790480

Questions about this trial

What is this clinical trial studying?

An observational study of Wounds, run by University Health Network, Toronto at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 May 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

wound size, bacterial load (time frame: 3 weeks after imaging with device). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01378728, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in